J&J beats Tagris­so and Take­da to the punch in key NSCLC sub­set, pick­ing up new FDA ap­proval

Look­ing to out­flank As­traZeneca’s best-sell­ing drug in a non-small cell lung can­cer niche, J&J scored an im­por­tant ap­proval Fri­day af­ter­noon.

Reg­u­la­tors gave the thumbs-up to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER